Free Trial

Immunocore Q3 2023 Earnings Report

Immunocore logo
$29.32 -0.32 (-1.08%)
As of 04:00 PM Eastern

Immunocore EPS Results

Actual EPS
$0.04
Consensus EPS
-$0.32
Beat/Miss
Beat by +$0.36
One Year Ago EPS
N/A

Immunocore Revenue Results

Actual Revenue
$62.89 million
Expected Revenue
$59.62 million
Beat/Miss
Beat by +$3.27 million
YoY Revenue Growth
N/A

Immunocore Announcement Details

Quarter
Q3 2023
Time
N/A
Remove Ads

Immunocore Earnings Headlines

Immunocore (NASDAQ:IMCR) Shares Gap Up on Insider Buying Activity
While Markets Slide, These "Genesis Cog" Trades Are Up Double-Digits
While most investors are struggling in today's volatile market, a small group of traders are quietly booking consistent gains. Just last week, our Genesis Cog subscribers captured an 11.51% gain shorting JEF, another 8.57% on CAKE, and 4.78% on RJF—all while the broader indexes continued their downward trend.
HC Wainwright Reaffirms Buy Rating for Immunocore (NASDAQ:IMCR)
Immunocore reports promising HIV trial results
See More Immunocore Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immunocore? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunocore and other key companies, straight to your email.

About Immunocore

Immunocore (NASDAQ:IMCR), a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

View Immunocore Profile

More Earnings Resources from MarketBeat